

# Lucia Del Vecchio

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9221625/publications.pdf>

Version: 2024-02-01

14  
papers

1,020  
citations

1162367

8  
h-index

1125271

13  
g-index

14  
all docs

14  
docs citations

14  
times ranked

1324  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 10-25.	0.4	30
2	The treatment of membranous nephropathy: a journey in the search for evidence. <i>Journal of Nephrology</i> , 2022, , 1.	0.9	0
3	The evolution of the therapeutic approach to membranous nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 768-773.	0.4	5
4	Intravenous iron therapy and the cardiovascular system: risks and benefits. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1067-1076.	1.4	12
5	Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 267-274.	0.4	13
6	Ferric Carboxymatose in Non-Hemodialysis CKD Patients: A Longitudinal Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1322.	1.0	2
7	A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease. <i>Drugs</i> , 2021, 81, 1491-1511.	4.9	18
8	Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series. <i>Brain Sciences</i> , 2021, 11, 1341.	1.1	7
9	Nefecon (targeted-release formulation-budesonide) for the treatment of IgA nephropathy. <i>Future Rare Diseases</i> , 2021, 1, .	0.1	2
10	Rituximab Therapy for Adults with Nephrotic Syndromes: Standard Schedules or B Cell-Targeted Therapy?. <i>Journal of Clinical Medicine</i> , 2021, 10, 5847.	1.0	11
11	Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. <i>Lancet, The</i> , 2017, 389, 2117-2127.	6.3	278
12	Impact of European medicines agency recommendations for hypersensitivity reactions on intravenous iron prescription in haemodialysis centres of the Lombardy region. <i>Journal of Nephrology</i> , 2016, 29, 673-681.	0.9	8
13	Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1346-1359.	0.4	628
14	Is it the agent or the blood pressure level that matters for renal and vascular protection in chronic nephropathies?. <i>Kidney International</i> , 2005, 67, S15-S19.	2.6	6